secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001628280-25-049561
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Biotech Q3 net loss $163M ($1.17/sh); ECLIPSE enrollment ahead of schedule
------------------------------------------------------------------------------

- Net loss $163.1M ($1.17/sh) vs $213.7M ($1.56) in Q3 2024; revenues $0.2M.
- Cash and investments $810.7M as of Sept 30, 2025; runway into mid-2027.
- ECLIPSE 1 enrollment completed ~2 months early; topline data for all three HDV studies expected Q1 2027.
- VIR-5500 first patient dosed in combo with ARPIs in 1L mCRPC; comprehensive data update planned Q1 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828025049561/0001628280-25-049561-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828025049561/vir-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-049561

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer